Small numbers of residual malignant cells are associated with clinical relapse at a later date.  Hematologics is the leader in residual disease testing by flow cytometry using a difference-from-normal approach.  We also offer a comprehensive menu of quantitative PCR assays for translocations, flow cytometric cell sorting, and molecular profiling by DNA analysis.

Hematologics has found that 30% of all cytopenias are associated with abnormal myeloid cells.  With our unique Flow Cytometric analysis, we assign an MDS Flow score that is associated with Myelodysplastic syndromes. We also offer aCGH/SNP microarray (LOH), Fish panels, cytogenetic karyotypes, and comprehensive DNA mutation panels.

Hematologics combines plasma cell enrichment and plasma cell sorting for FISH and aCGH/SNP  microarray  analysis for the diagnosis, prognosis and monitoring of plasma cell neoplasms.  For patients with concurrent monoclonal B-cell and plasma cell populations, we offer PCR IGH monoclonality profiling and MYD88 on the sorted populations to establish diagnosis.

Hematologics has extensive experience analyzing biopsies from patients on clinical trials, including those treated with novel therapies.  Please contact us to find out more how we can help clinical trial monitoring or assessment of new drug targets for the treatment of myeloid or lymphoid neoplasms.